



Radiotherapy for Prostate Cancer

Guest Editors:

Dr. Berardino De Bari

Dr. Letizia Deantonio

Dr. Pierfrancesco Franco

Deadline for manuscript
submissions:

closed (30 November 2023)

Message from the Guest Editors

We are pleased to invite you to submit your original contributions, studies, trial protocols and reviews dealing with innovative aspects of radiotherapy for PCa. For this Special Issue, we welcome any manuscript focusing on basic, clinical, and psychosocial research on radiotherapy and PCa. Research areas may include (but are not limited to) the following:

Surveillance imaging and innovative diagnostic work up for PCa patients before and after RT; Combination of radiotherapy with systemic treatments for PCa patients; Moderate and extreme hypofractionation for PCa patients; Multidisciplinary approach to PCa; Radiomics and radiogenomics; IGRT and adaptive radiotherapy for PCa patients; Prognostic and predictive factors for PCa patients treated with RT; Modern brachytherapy techniques; Reirradiation in radio-recurrent PCa patients; Oligometastatic disease; Supportive therapy; Quality of life and patient reported outcomes.

We look forward to receiving your contributions.

Dr. Berardino De Bari

Dr. Letizia Deantonio

Dr. Pierfrancesco Franco





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada

2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada

Message from the Editor-in-Chief

I am honored and enthusiastic to serve as Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **MEDLINE**, **PMC**, **Embase**, and **other databases**.

Journal Rank: JCR - Q2 (Oncology)

Contact Us

Current Oncology Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/currnconcol
currentoncology@mdpi.com
[X@CurrentOncology](https://twitter.com/CurrentOncology)